Content Type: Commentary & Opinion

Healing Our De-Commissioned FDA

May 18, 2026

Clinical Implementation of Multi-Cancer Early Detection Tests: Can We Find a Path Forward?

May 17, 2026

Op-Ed: Congress Can Finally Stop Big Pharma’s Patent Abuse

May 4, 2026

Op-Ed: Congress Must Repair USPTO’s Inter Partes Review Process

May 4, 2026

Reforming Payment for Clinician-Administered Drugs — Most-Favored-Nation Pricing in Medicare Part B

May 4, 2026

Deeming Doesn’t Deliver: Reliance on Foreign Regulators Targets the Wrong Stage of Canadian Drug Access

May 1, 2026

Anticompetitive Mergers — Pharmaceutical Buyouts as a Strategy for Maintaining Market Dominance

April 27, 2026

Closing the Evidence Gap for Drugs in Children — Measures to Strengthen the Pediatric Research Equity Act

April 27, 2026

Skinny Labels at the Supreme Court—Generic Competition, Patent Inducement, and Affordable Medicines

April 11, 2026

Using Behavioral Economics to Promote Physicians’ Prescribing of Generic Drugs and Follow-On Biologics: What Are the Issues?

April 9, 2026

Introduction: Behavioral Economics and the Doctor-Patient Relationship

April 9, 2026

Views from Academia, Industry, Regulatory Agencies, and the Legal System (3rd Ed)

April 9, 2026